Barclays PLC Adaptimmune Therapeutics PLC Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Barclays PLC holds 50,061 shares of ADAP stock, worth $56,568. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50,061
Previous 50,061
-0.0%
Holding current value
$56,568
Previous $40,000
97.5%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding ADAP
# of Institutions
84Shares Held
160MCall Options Held
42.8KPut Options Held
42.1K-
Matrix Capital Management Company, LP Waltham, MA39MShares$44 Million0.57% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$31 Million1.23% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$19.3 Million1.89% of portfolio
-
Baillie Gifford & CO15.9MShares$17.9 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY10.8MShares$12.2 Million0.22% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $185M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...